The table below reports 14 separate 2x2 tables of counts from 
14 separate clinical trials of the breast cancer drug Tamoxifen. 
Each was a randomized, prospective clinical trial that studied 
women with early breast cancer split into two groups: treatment 
versus control. The treatment group received Tamoxifen treatment 
for an average of about one year, the control group received no
treatment (some treatment and controls included chemotherapy too). 
 The ``endpoint'' for the trials was breast cancer 
recurrence, so that each of the 14 studies delivers data in the 
form of ``two binomials'' informing on the relative risk 
(treatment versus control) of breast cancer recurrence. In the 
table, for each trial we have y0 recurrences out of the n0 in
the control group, and y1 recurrences out of the n1 in the
treatment group. 


TRIAL     y1     n1     y0     n0

 1        55     97     67    101 
 2       137    282    187    306 
 3       505    927    590    915 
 4        62    123     74    140 
 5        99    239    118    236  
 6        50    130     49    107 
 7       185    311    200    319 
 8       186    303    187    307 
 9       148    325    178    325 
 10       25     79     38     86  
 11      223    344    224    350 
 12      183    937    185    936  
 13        2     12      0      8  
 14      129    434    159    449 



The data was presented by the Early Breast Cancer Trials 
Collaborative Group as reported in the 1998 paper 
"Tamoxifen for early breast cancer: an overview of the
 randomised trials", The Lancet,  351, 1451-1467.

I'm grateful to Giovanni Parmigiani for providing this data.